We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Device Detects Brain Tumors Using Urine

By LabMedica International staff writers
Posted on 06 Feb 2023
Print article
Image: Microscopic image of the nanowires (Photo courtesy of Nagoya University)
Image: Microscopic image of the nanowires (Photo courtesy of Nagoya University)

There has recently been an improvement in cancer survival rates due to early detection of the disease, although the survival rate for brain tumors has remained almost the same for the last 20 years, partly due to their late detection. Brain tumors are often discovered only after the onset of neurological symptoms, such as loss of movement or speech, by when the tumor achieves a considerable size. Detecting the tumor when it is still small and commencing treatment as soon as possible can help save lives. Now, researchers have used a new device to identify a key membrane protein in urine that indicates whether a person has a brain tumor. By using the protein to detect brain cancer, it will be possible to avoid invasive tests and increase the chances of the tumor being detected at an early enough stage for surgery. The finding could also have potential implications for detecting other types of cancer.

The presence of tumor-related extracellular vesicles (EVs) in urine can indicate that a person has a brain tumor. EVs are nano-sized vesicles that perform various functions, including cell-to-cell communication. The EVs found in brain cancer patients have specific types of RNA and membrane proteins, allowing them to be used for detecting the presence of cancer and its progression. EVs are excreted far from the brain, but many EVs from cancer cells still exist stably and are excreted in the urine without breaking down.

Researchers at Nagoya University (Nagoya, Japan) have developed a new analysis platform for brain tumor EVs using nanowires at the bottom of a well plate. They used the device to identify two specific types of EV membrane proteins, known as CD31/CD63, from the urine samples of brain tumor patients. By looking for these tell-tale proteins, doctors can identify tumor patients before they develop symptoms. Additionally, urine testing offers several advantages and is an effective, simple, and non-invasive method because urine contains many informative biomolecules that can be traced back to identify the disease.

“Currently, EV isolation and detection methods require more than two instruments and an assay to isolate and then detect EVs,” said Associate Professor Takao Yasui of Nagoya University Graduate School of Engineering. “The all-in-one nanowire assay can isolate and detect EVs using one simple procedure. In the future, users can run samples through our assay and change the detection part, by selectively modifying it to detect specific membrane proteins or miRNAs inside EVs to detect other types of cancer. Using this platform, we expect to advance the analysis of the expression levels of specific membrane proteins in patients’ urinary EVs, which will enable the early detection of different types of cancer.”

Related Links:
Nagoya University 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.